ALDOSTERONE ANTAGONISTS IN CLINICAL MEDICINE

Proceedings of the Searle symposium, Nice, 1978

Excerpta Medica

ALDOSTERONE ANTAGONISTS IN CLINICAL MEDICINE

Proceedings of the Searle symposium, Nice, April 13-15, 1978

1978

EXCERPTA MEDICA, Amsterdam - Oxford

International Congress Series No. 460

ISBN Excerpta Medica 90 219 0387 3

ISBN Elsevier North-Holland 0444 90062 4

Library of Congress Cataloging in Publication Data
Main entry under title:

Aldosterone antagonists in clinical medicine.

Includes index.
1. Heart--Diseases--Chemotherapy--Congresses.
2. Aldosterone antagonists--Congresses. 3. Spironolactone--Congresses. I. Corvol, P. II. Searle (G.D.) and Company.
RC 684.A44A42 615'.71 78-21645

Publisher:
Excerpta Medica
305 Keizersgracht
Amsterdam
P.O. Box 1126

Sole Distributors for the USA and Canada:
Elsevier/North-Holland Inc.
52 Vanderbilt Avenue
New York, NY 10017

Printed in The Netherlands by Groen, IJmuiden

Session IV. Cardiac, hepatic and cerebral aspects

The effect of spirolactone and spironolactone on plasma testosterone in man

John-Fredrik Dymling

Department of Endocrinology, Lund University, Malmö General Hospital, Malmö, Sweden

Summary

Both acute and chronic administration of spirolactone and spironolactone decreases plasma testosterone in man. The mechanism of this decrease was studied in a series of experiments. These studies demonstrated that the effect of spirolactone involves an increased elimination of testosterone, whereas gonadotrophin release and testicular production and release do not seem to be affected. The increased elimination of testosterone following spirolactone is apparently due neither to induction of glucuronyltransferase, sulphatase or the reductases, nor to increased conversion of testosterone to estradiol, at least not in acute experiments. The most likely explanation seems to be that spirolactone displaces testosterone from the binding plasma proteins.

Introduction

Spirolactone and spironolactone are chemically similar to progesterone and have a slight progestational activity (Hertz and Tullner, 1958). Administration of these compounds causes side effects such as gynaecomastia, impotence and menstrual disturbances. Progesterone preparations have been shown to decrease plasma testosterone in males (Gordon et al., 1970; Sundsfjord et al., 1971). A rapid decrease of plasma testosterone following spirolactone has also been reported (Dymling et al., 1972). How exactly spirolactone brings this effect about has not been elucidated. This has prompted the studies reported here.

Methods

The spirolactone used was Soludactone (canrenoate potassium, potassium-3-(3-oxo-17β-hydroxy-4,6-androstadione-17α-γ1)-propanoate) which was administered intravenously as rapid single injections in doses of 100 or 200 mg. The spironolactone used was Aldactone (3-(3-oxo-7α-acetylthio-17β-hydroxy-androst-4-en-17α-4γ1)-propanoic acid lactone).

17-Ketosteroids were determined according to the method of Vestergaard (1951) and 17-hydroxycorticosteroids as described by James and Caie (1964).

Testosterone and androstenedione in the plasma were determined using a double isotope technique (Grandy and Petersson, 1968) except for the 'estradiol study' where plasma testosterone was determined by radioimmunoassay.

The gonadotrophins, FSH and LH, and estradiol in the plasma were determined by radioimmunoassay.

Clinical material

The studies were performed in ambulatory healthy individuals and in hospitalized patients under metabolic ward conditions. Plasma samples were drawn as stated. When not indicated the studies were performed in the morning after an overnight fast.

Results

Methodological interference between spirolactone and spironolactone was studied in vitro. The results are reported in Tables 1 and 2. There were no indications of such interference. The effects of spirolactone and spironolactone on plasma gonadotrophins, FSH and LH, are presented in Tables 3 and 4. No effect could be demonstrated. The effect of spirolactone on the conversion of androstenedione to testosterone has previously been reported (Dymling et al., 1972). One additional study is reported here. It demonstrates a rapid fall of plasma testosterone in a female, without demonstrable alterations of plasma androstenedione (Table 5).

The effects of spirolactone on plasma testosterone in two males in whom the testosterone was obtained after intramuscular injections of testosterone esters are shown in Figures 1 and 2. The same rapid fall of plasma testosterone was found as in males with intact endogenous production of testosterone.

The effects of spironolactone on 17-ketosteroids and 17-hydroxycorticosteroids have previously been reported (Dymling et al., 1972). 17-Ketosteroid excretion progressively decreased, whereas 17-hydroxycorticosteroid excretion remained unaltered.

The acute effect of spirolactone on testosterone and estradiol in the plasma is shown in Table 6. The rapid fall of plasma testosterone was not accompanied by a simultaneous increase in plasma estradiol.

Discussion

Spirolactone causes a rapid, transient fall of plasma testosterone. This can in principle be an effect of decreased production or increased elimination. The aim of the reported studies was to explore which of these mechanisms is operative.

Decreased production can be due to a direct effect of spirolactone on testosterone production and/or release, an indirect effect mediated via pituitary gonadotrophins or a decreased conversion of androstenedione to testosterone. In the studies presented there were no demonstrable effects on FSH and LH. It should, however, be kept in mind that chronic administration of spironolactone caused a decrease of plasma testosterone connected with an increase of LH in five of seven healthy males (Pentikäinen et al., 1973). As a consequence, it is possible that the clinically recognized side effects, which are the results of chronic administration, are connected with additional hormonal changes, not involved in the acute changes following spirolactone.

The conversion of androstenedione to testosterone is not affected by spirolactone (Dymling et al., 1972). The effect of spirolactone on testicular production and release has not been studied directly but such an effect seems highly unlikely. In two patients in whom plasma testosterone was obtained after intramuscular injections spirolactone caused an analogous decrease of plasma testosterone.

It is therefore concluded that the decrease of plasma testosterone following spiro-

Table 1. Plasma from a 41-year-old healthy male was analyzed before and after in vitro addition of 1 mg of spirolactone per 10 ml.

	Testosterone μg/100 ml	Androstenedione μg/100 ml
Plasma	0.72	0.16
	0.72	0.15
Plasma + spirolactone	0.69	0.15
	0.72	0.14

Table 2. Plasma samples from J.F.D., 41-year-old healthy male, and from E.J., 53-year-old male with essential hypertension on spironolactone 200 mg daily perorally, were analyzed separately and after mixing. Each sample was analyzed twice.

	Testosterone μg/100 ml	Androstenedione μg/100 ml
J.F.D.	0.67	0.09
	0.63	0.10
E.J.	0.54	0.11
	0.52	0.10
J.F.D. + E.J.	0.51	0.09
	0.62	0.10

nolactone administration is not an effect on testosterone production but rather an effect on testosterone elimination. Testosterone is metabolized by the liver enymes glucuronyltransferase and sulphatase 5β-reductase, and converted to estradiol. 17-Ketosteroids progressively decrease during spironolactone administration (Nocke et al., 1971; Dymling et al., 1972; Pentikäinen et al., 1973), which has been interpreted as a competitive inhibition of steroid-conjugating enzymes (Nocke et al., 1971). The results do not imply an increased elimination of testosterone by the liver. Furthermore spirolactone does not influence the prostate 5α-reductase activity (Corvol et al., 1976).

The very limited number of observations reported here did not demonstrate any acute effect of spirolactone on the conversion of testosterone to estradiol. However, two weeks treatment with spironolactone caused an increase in urinary output of 17β-estradiol as well as estriol and estrone (Pentikäinen et al., 1974). Also the blood estradiol levels increased in six patients treated with spironolactone who developed gynecomastia (Rose et al., 1977). However, an increased conversion of testosterone to estradiol may become apparent only on chronic administration of spironolactone but cannot explain the acute effect on plasma testosterone.

The remaining possibility is a competitive displacement of testosterone from testosterone-binding plasma proteins. Such a displacement has been demonstrated by Caminos-Torres et al. (1977). An increased metabolic clearance rate of testosterone has also been demonstrated. These two facts could be connected since testosterone itself increases the metabolic clearance rate of testosterone (Southren et al., 1973). The sequence of events could consequently be the following: Spironolactone displaces testosterone from protein binding sites. The free testosterone causes an increased metabolic clearance rate of testosterone. This does not seem to occur via either of the established pathways of testosterone metabolism. One possibility is increased excretion in the urine. Measurements of urinary excretion of testosterone have to our knowledge not

Table 3. FSH and LH in 3 menopausal women (B.J., U.N. and B.R.), one woman with idiopathic oedema (I.G.) and 3 males, one with primary hypogonadism (C.S.), one with renovascular hypertension (D.P.) and one with Addison's disease

Time in hours	Spirolactone (mg i.v.) spironolactone (mg p.o.)	B.J. F 55 yr		U.N. F 51 yr		B.R. F 58 yr		I.G. F 36 yr		C.S. M 19 yr		D.P. M 50 yr		M.A. M 71 yr	
		FSH (ng/ml)	LH (ng/ml)	FSH (ng/ml)	LH (ng/ml)	FSH (ng/ml)	LH (ng/ml)	FSH (ng/ml)	LH (ng/ml)	FSH (ng/ml)	LH (ng/ml)	FSH (ng/ml)	LH (ng/ml)	FSH (ng/ml)	LH (ng/ml)
0	200 mg i.v.	10.4	5.9	11.5	6.1	7.8	3.5	4.0	1.6	17.5	4.5	6.2	2.6	2.4	2.1
0.5		10.8	5.0	9.7	5.3	–	–	3.9	2.3	15.9	4.2	5.1	2.1	2.7	2.1
1.0		12.0	5.1	9.0	5.4	–	–	4.4	1.7	17.6	4.6	5.4	1.9	2.5	2.1
2.0		14.2	4.5	10.0	5.7	–	–	3.6	1.7	15.8	3.7	5.8	1.4	2.9	2.7
4.0		14.5	5.3	10.2	6.8	–	–	3.9	1.7	16.9	5.3	–	–	2.5	1.8
8.0		12.1	5.3	10.1	4.8	–	–	3.8	1.4	14.6	3.8	8.1	1.3	2.7	1.9
12.0	200 mg i.v.	11.1	5.2	15.7	5.0	–	–	3.3	1.8	–	–	–	–	2.4	1.9
24.0	150 mg p.o.	11.8	4.4	14.9	5.4	10.5	3.6	4.3	1.8	13.1	4.1	6.5	1.6	2.7	1.9
48	150 mg p.o.	12.3	5.4	14.3	6.3	10.2	3.8								
72	150 mg p.o.	12.1	5.4	13.4	5.8										
96	150 mg p.o.	–	–	15.0	5.3	7.4	6.0								
120	150 mg p.o.	–	–	12.8	5.8										
144	150 mg p.o.	–	–	17.0	6.4	11.6	3.7								
168	150 mg p.o.	12.9	4.1	12.5	5.5	8.6	4.9								

Table 4. FSH and LH in a 58-year-old healthy female. Spirolactone, 200 mg intravenously, was given at 0900 hours

Time	FSH (ng/ml)	LH (ng/ml)
0830	12.5	11.8
0855	11.6	11.5
0905	12.5	11.4
0910	12.5	13.25
0915	12.5	11.4
0930	11.1	10.9
1000	9.3	12.2
1100	11.6	10.41
1300	8.3	8.7

Table 5. p-Testosterone and p-androstenedione in a 25-year-old female with idiopathic oedema. Spirolactone, 100 mg intravenously, was administered at 0800 hours

Time	P-testosterone (μg/100 ml)	P-androstenedione (μg/100 ml)
0759	0.024	0.084
0815	0.012	0.063
0830	0.008	0.084
0900	0.023	0.055
1000	0.016	0.060
1200	0.012	0.068
1600	0.001	0.052
2000	0.008	0.041



Fig. 1. The effect of spironolactone on plasma testosterone and androstenedione in a male with panhypopituitarism, where the testosterone was obtained after intramuscular injections of testosterone esters.

Fig. 2. The effect of spirolactone on plasma testosterone in a male with primary hypogonadism and exogenously administered testosterone.

Table 6. p-Testosterone and p-estradiol in a healthy male (R.A.) and a male with cardiac decompensation. Spirolactone: 200 mg intravenously, was given on day 2 at 1200 hours

	R.A. M 54 yr				F.Ö. M. 73 yr			
	Testosterone (nmol/l)		Estradiol (pmol/l)		Testosterone (nmol/l)		Estradiol (pmol/l)	
Time	day 1	day 2	day 1	day 2	day 1	day 2	day 1	day 2
0800	20	18	70	130	31	26	190	60
1159	16	15	100	60	25	12	110	110
1215	16	8.0	100	90	20	7.0	90	100
1230	14	8.0	90	50	22	6.0	140	130
1245	14	9.0	60	90	21	7.0	90	130
1300	15	8.0	70	110	22	13.0	140	140
1400	12	8.0	70	70	19	11	90	110
1600	15	11	70	60	19	11	110	110
2000	15	10	80	110	19	10	110	110
2400	15	12	90	110	20	17	120	130

been performed in acute experiments. Pentikäinen et al. (1974) found no alteration in urinary testosterone after two weeks of treatment with spironolactone.

References

Caminos-Torres, R., Ma, L. and Snyder, P.J. (1977): *J. clin. Endocr., 45,* 255.

Corvol, P., Mahoudeau, J.A., Valcke, J.-C., Ménard, J. and Bricaire, H. (1976): *Nouv. Presse méd. 5,* 691.

Dymling, J.-F., Nilsson, K.O. and Hökfelt, B. (1972): *Acta endocr. (Kbh.), 70,* 104.

Gandy, H.M. and Petersson, R.E. (1968): *J. clin Endocr., 28,* 949.

Gordon, G.G., Southren, A.L., Tochimoto, S., Olivo, J., Altman, K., Rand, J. and Lemberger, L. (1970): *J. clin. Endocr., 30,* 449.

Hertz, R. and Tullner, W.W. (1958): *Proc. Soc. exp. Biol. Med. (N. Y.), 99,* 451.

James, V.H.T. and Caie, E. (1964): *J. clin. Endocr., 24,* 180.

Nocke, L., Breuer, H., Klink, R. Lichton, I.R. and Nocke, W. (1971): *Acta endocr. (Kbh.), Suppl. 152,* 41.

Pentikäinen, P.J., Pentikäinen, L.A., Huffman, D.H. and Azarnoff, D.L. (1974): *J. int. med. Res., 2,* 439.

Rose, L.I., Underwood, R.H., Newmark, S.R., Kisch, E.S. and Williams, G.H. (1977): *Ann. intern. Med., 87,* 398.

Southren, A.L., Gordon, G.G., Olivo, J., Rafii, F. and Rosenthal, W.S. (1973): *Metabolism, 22,* 695.

Sundsfjord, J.A., Aakvaag, A. and Norman, N. (1971): *J. Reprod. Fert., 26,* 263.

Vestergaard, P. (1951): *Acta endocr. (Kbh.), 8,* 192.